For instance, prostate cancer antigen 3 (PCA3), the first FDA-approved lncRNA, appears as a promising and pragmatic biomarker for supporting PCa diagnosis (Sartori and Chan, 2014; Sánchez-Salcedo et al., 2021). This evidence concerns the gene PCA3 and posterior cortical atrophy.